190 related articles for article (PubMed ID: 30305158)
1. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER.
Bethencourt Baute JJ; Sanchez-Piedra C; Ruiz-Montesinos D; Medrano San Ildefonso M; Rodriguez-Lozano C; Perez-Pampin E; Ortiz A; Manrique S; Roselló R; Hernandez V; Campos C; Sellas A; Sifuentes-Giraldo WA; García-González J; Sanchez-Alonso F; Díaz-González F; Gómez-Reino JJ; Bustabad Reyes S;
Arthritis Res Ther; 2018 Oct; 20(1):227. PubMed ID: 30305158
[TBL] [Abstract][Full Text] [Related]
2. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
4. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
7. A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry.
Batthish M; Berard R; Cabral D; Bolaria R; Chédeville G; Duffy C; Gerhold K; Gerschman T; Huber A; Proulx-Gauthier JP; Rosenberg A; Rumsey D; Schmeling H; Shiff N; Soon G; Bruns A; Tucker L; Guzman J;
Rheumatology (Oxford); 2020 Oct; 59(10):2796-2805. PubMed ID: 32044978
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
Niewerth M; Minden K; Klotsche J; Horneff G
Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
[TBL] [Abstract][Full Text] [Related]
9. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
11. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of High-Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance.
Correll CK; Shrader P; Dennos A; Phillips T; Shiff NJ; Verstegen RHJ; Beukelman T;
Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1770-1779. PubMed ID: 34121344
[TBL] [Abstract][Full Text] [Related]
13. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
[TBL] [Abstract][Full Text] [Related]
14. A controversial topic in juvenile idiopathic arthritis: Association between biologic agents and malignancy.
Koker O; Sahin S; Adrovic A; Yildiz M; Barut K; Gulle B; Eker Omeroglu R; Kasapcopur O
Int J Rheum Dis; 2020 Aug; 23(9):1210-1218. PubMed ID: 32691529
[TBL] [Abstract][Full Text] [Related]
15. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
17. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
18. Outcome of adult patients with JIA treated with the biosimilar Benepali
Vollbach K; Tenbrock K; Wagner N; Horneff G; Klein A; Foeldvari I; Haas JP; Aries P; Gauler G; Striesow F; Hoff P; Scholz C; Tatsis S; Seipelt E; Klotsche J; Minden K
Arthritis Res Ther; 2022 Dec; 24(1):271. PubMed ID: 36514116
[TBL] [Abstract][Full Text] [Related]
19. [Biological therapy in juvenile idiopathic arthritis].
Neve-Græsbøll A; Glerup M; Herlin T
Ugeskr Laeger; 2022 Mar; 184(13):. PubMed ID: 35499221
[TBL] [Abstract][Full Text] [Related]
20. High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting.
Brunelli JB; Schmidt AR; Sallum AME; Goldenstein-Schainberg C; Bonfá E; Silva CA; Aikawa NE
Mod Rheumatol; 2018 Mar; 28(2):264-270. PubMed ID: 28949278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
